Trials / Completed
CompletedNCT00487058
A Phase I Dose Escalation Study of LBQ707 (Gimatecan) Administered Orally Twice Per Week to Japanese Patients With Advanced Solid Tumors
A Phase I Dose Escalation Study of LBQ707 (Gimatecan) Administered Orally Twice Per Week to Japanese Patients With Advanced Solid Tumors.
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 28 (estimated)
- Sponsor
- Novartis · Industry
- Sex
- All
- Age
- 20 Years
- Healthy volunteers
- Not accepted
Summary
This study assesses the tolerability, safety, efficacy and pharmacokinetics of gimatecan in Japanese patients. Gimatecan is administered orally twice per week, every 28 days, to adult patients with advanced solid tumors who have progressed despite standard therapy or for whom standard systemic therapy dose not exist.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Gimatecan |
Timeline
- Start date
- 2007-05-01
- Primary completion
- 2008-06-01
- First posted
- 2007-06-15
- Last updated
- 2009-11-19
Locations
1 site across 1 country: Japan
Source: ClinicalTrials.gov record NCT00487058. Inclusion in this directory is not an endorsement.